CureVac B.V

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CureVac (CVAC) announces final analysis from its HERALD study on CVnCoV showing efficacy of 48%.

CureVac (CVAC) Announces Final Analysis of its COVID-19 Vaccine Study

CureVac plans to continue work on its Covid-19 vaccine despite disappointing clinical trial results that showed the shot is just 48% effective.

CureVac to 'plow forward' with Covid vaccine despite disappointing results

The German biotech company CureVac BV (NASDAQ: CVAC) announced on Wednesday after hours the final results of its late-stage COVID-19 vaccine trial showing 48% effectiveness at preventing the disease, which is slightly higher than seen in a preliminary readout. But it lagged the efficacy rates of more than 90% shown by Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) and Moderna Inc's (NASDAQ: MRNA) mRNA shots.

CureVac Stock Drops After Final Results Confirm Its COVID-19 Vaccine Trails Rivals

German company CureVac released the final results for its once-promising Covid-19 vaccine, finding it provided less protection than the vaccines already authorized for use in the U.S.

The Wall Street Journal: CureVac says COVID-19 vaccine was 48% effective in key study

CureVac (NASDAQ: CVAC) shares are trading higher after the company announced the appointment of Dr. Malte Greune as COO and the transition of Dr. Florian von der Mülbe to lead accelerated development of the RNA printer. Dr. Greune joins the company from Sanofi-Aventis Deutschland, where he held multiple management positions.

Why Shares Of CureVac Are Trading Higher On Wednesday

Things are looking bleak right now, but they might improve with enough time.

Without a Coronavirus Vaccine Of Its Own, Is There Any Hope For CureVac Stock?

CureVac's first COVID vaccine candidate disappointed investors. But a second one looks promising.

Could CureVac Be a Millionaire-Maker Stock?

AstraZeneca

Moderna

Pfizer

Bad news for AstraZeneca and CureVac should mean more good news for Pfizer and Moderna.

How Pfizer and Moderna Could Profit Big-Time From AstraZeneca's and CureVac's Challenges

German financial watchdog BaFin is investigating possible insider trading of vaccine maker's CureVac shares, which fell after the biotech firm announced its COVID-19 vaccine proved only 47% effective, Rheinische Post newspaper reported on Monday.

Germany's BaFin looking into possible insider trading of CureVac shares

This coronavirus vaccine developer just hit a massive stumbling block.

Why Is Everyone Talking About CureVac Stock?

CureVac BV (NASDAQ:CVAC) shares are trading higher by 14% at $66.16 as the stock rebounds after falling in recent sessions. The stock dipped after the company late Wednesday announced its COVID-19 vaccine demonstrated an interim vaccine efficacy of 47% and did not meet its prespecified statistical success criteria.

CVAC Stock Price Increases 14%: Why It Happened

The CEO of the German company said on Thursday that CureVac hoped its vaccine candidate could still be of use after trial data showed it was a failure.

CureVac Says Its Not Giving Up on a Covid-19 Vaccine and The Shares Are Soaring.

The news may reinforce Moderna's and Pfizer's vaccine-market dominance.

12 Words From CureVac's CEO That Could Mean Billions for Moderna and Pfizer

Shares of Curevac rose 10% in premarket trading on Friday. Shares of the German biotech have lost 48% this week after the company said a late-stage clinical trial of its COVID-19 vaccine was only 47% effective.

Curevac shares climb 10%; CFO says not giving up on COVID-19 vaccine

CureVac N.V.'s (NASDAQ: CVAC) Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the Financial Times reported on Thursday.

Tesla Partner CureVac Says Will Find 'Sweet Spot' For COVID-19 Vaccine Despite Disappointing Data

CureVac (CVAC) down as it announces that its first-generation COVID-19 vaccine candidate, CVnCoV, did not meet the prespecified statistical success criteria in a phase IIb/III study.

CureVac (CVAC) Plummets on Disappointing COVID-19 Vaccine Data

CureVac NV (NASDAQ: CVAC) slipped about 45% in the stock market on Thursday morning as the company said the late-stage trial showed its candidate COVID-19 vaccine to be only 47% effective, raising questions on the German biotech's agreement with the European Union to deliver hundreds of millions of doses of its vaccine (CVnCoV). CureVac's shot […] The post CureVac collapses 45% after disappointing results from COVID-19 vaccine trial appeared first on Invezz.

CureVac collapses 45% after disappointing results from COVID-19 vaccine trial

The biotech's COVID-19 vaccine candidate no longer appears to be viable.

Why CureVac Stock Is Getting Crushed Today

One of the worst stocks on the Nasdaq this morning, the shares of CureVac BV (NASDAQ:CVAC) are spiraling, last seen down 48.8% to trade at $48.49.

Options Traders Swam Spiraling CureVac Stock

Shares in CureVac plummeted on Thursday after the German biotech company said that interim trial results showed its experimental Covid-19 vaccine was only 47% effective in preventing symptomatic disease.

CureVac shares drop 45% after disappointing Covid vaccine results

CureVac shares crashed after the German biotech said its Covid-19 vaccine was only 47% effective in preventing the disease. The post CVAC Stock: The Huge Covid-19 News That Has CureVac Plunging Today appeared first on InvestorPlace.

CVAC Stock: The Huge Covid-19 News That Has CureVac Plunging Today

Shares of CureVac fell 42% in premarket trading on Thurdsay, a day after the German biotech said its COVID-19 vaccine was 47% effective in preventing the disease. CureVac's study, conducted in 10 countries and involving 40,000 people, showed the vaccine's struggle against a "fast changing environment" of at least 29 COVID-19 variants, with the original coronavirus strain "almost completely absent.

CureVac tumbles 41% in premarket on COVID-19 vaccine disappointment

Interim analysis of data from about 40,000 volunteers showed the biotech's jab is only 47% effective, falling short of the study's criteria.

German biotech CureVac's stock plunges 50% after its COVID-19 vaccine candidate failed a clinical trial

The global tally for the coronavirus-borne illness headed above 177 million on Thursday, according to data aggregated by Johns Hopkins University, while deaths climbed above 3.8 million. The U.S. continues to lead the world in total cases at 33.49 million, while deaths total 600,653.

Coronavirus tally: Global cases of COVID-19 top 177 million and CureVac vaccine is just 47% effective

The stock price of CureVac BV (NASDAQ: CVAC) fell by over 45% pre-market. This is why it happened.

News for CureVac B.V Stock (CVAC)